Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia

Sponsor
Ciusss de L'Est de l'Île de Montréal (Other)
Overall Status
Completed
CT.gov ID
NCT03148639
Collaborator
Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal (Other)
19
1
2
27
0.7

Study Details

Study Description

Brief Summary

Treatment of verbal hallucinations in schizophrenia is clinically challenging for both the patient and the therapist. For the therapist, one of the main difficulties arises from the impossibility of directly communicating with the entity persecuting the patient. For the patient, the therapeutic process is challenging because it aims at getting to better cope with an entity that keeps repeating stereotyped and abusive sentences without having the emotional strength to reply to the persecutor. To help overcome these clinical challenges, virtual reality enable patients to recreate the face and the voice of their persecutor.The hypothesis is that the engagement of patients in a dialogue with an external representation of their persecutor, with the support of the therapist, would help them to gain better control over their voices.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Avatar therapy
  • Other: Treatment-as-usual
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
19 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Partial crossover designPartial crossover design
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Emotion Regulation Using Virtual Reality in Schizophrenia: a Clinical and Mechanistic Trial of Avatar Therapy for Refractory Auditory Hallucinations
Actual Study Start Date :
Sep 1, 2015
Actual Primary Completion Date :
Mar 31, 2017
Actual Study Completion Date :
Dec 2, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Avatar therapy

Immediate Avatar therapy.

Behavioral: Avatar therapy
Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.

Other: Treatment-as-usual

Treatment-as-usual then delayed Avatar therapy.

Behavioral: Avatar therapy
Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.

Other: Treatment-as-usual
Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.

Outcome Measures

Primary Outcome Measures

  1. Change in Psychotic Symptom Rating Scale - auditory hallucinations [Within 1 week before treatment, within 1 week after treatment, follow-up 3 months]

    11-item structured interview assessing the severity of auditory hallucinations

Secondary Outcome Measures

  1. Change in Beliefs About Voices Questionnaire - Revised [Within 1 week before treatment, within 1 week after treatment, follow-up 3 months]

    35-item self-report measure designed to assess key beliefs and responses people have concerning their voice

  2. Change in Positive And Negative Syndrome Scale [Within 1 week before treatment, within 1 week after treatment, follow-up 3 months]

    30-item semi-structured interview investigating overall symptoms severity of schizophrenia in the last week

  3. Change in Beck Depression Inventory - II [Within 1 week before treatment, within 1 week after treatment, follow-up 3 months]

    21-item self-report measure assessing depression symptoms over the past 2 weeks

  4. Change in Quality of Life Enjoyment and Satisfaction Questionnaire - Short From [Within 1 week before treatment, within 1 week after treatment, follow-up 3 months]

    16-item self-report scale measuring enjoyment and satisfaction experienced during the past week in various areas of daily functioning

Other Outcome Measures

  1. Change in Self-reported anxiety, fear and presence [Last 10 min of each therapy session]

    3-item self-report scale, ranging from 0 (no emotion) to 10 (strongest emotion)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • distressing auditory verbal hallucinations

  • medication resistance relating to auditory verbal hallucinations (no response after 3 antipsychotics trials lasting at least 4 weeks each with a minimum of 400mg chlorpromazine equivalent)

  • DSM-5 diagnosis of schizophrenia or schizoaffective disorder

Exclusion Criteria:
  • any change in medication within the past 2 months;

  • substance use disorder within the last 12 months

  • neurological disorder or unstable and serious physical illness

  • ongoing psychotic episode

  • cognitive behavioural therapy for psychosis within the last 12 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut Universitaire en Santé Mentale de Montréal Montréal Quebec Canada H1N 3M5

Sponsors and Collaborators

  • Ciusss de L'Est de l'Île de Montréal
  • Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal

Investigators

  • Principal Investigator: Alexandre Dumais, MD, Ph.D, Institut Philippe Pinel de Montréal

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alexandre Dumais, Psychiatrist, researcher, Ciusss de L'Est de l'Île de Montréal
ClinicalTrials.gov Identifier:
NCT03148639
Other Study ID Numbers:
  • IPPM 14-006
First Posted:
May 11, 2017
Last Update Posted:
Jan 30, 2018
Last Verified:
Jan 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Alexandre Dumais, Psychiatrist, researcher, Ciusss de L'Est de l'Île de Montréal
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 30, 2018